A recent opening of Series A funding has made Berwyn-based QR Pharma the hub of fresh new leadership, and much of it centers on new board chairman Michael Hoffman, with his array of industry connections, and new director Dhesh Govender, with the attention that comes from his frequent Bloomberg TV guest analyst appearances.

“We are thrilled to have Michael and Dhesh on our board of directors,” CEO Maria L. Maccecchini said in a recent Herald Online report. “Michael brings a wealth of contacts in the financial and the research communities, and his experience will be invaluable to QR as it undertakes the continued clinical studies of its lead compound, Posiphen, in Alzheimer’s and Parkinson’s patients.”

Hoffman is also a partner in the energy investment firm Riverstone Holdings, chairman of both Onconova Therapeutics and Tara Immuno-Oncology, and a trustee for The Rockefeller University. Govender, an inventor and former NASA partner, now serves alongside Hoffman as CEO of Tara Immuno-Oncology.

Read much more about the extensive background of QR Pharma’s new leaders on HeraldOnline.com here.